471 patents
Page 22 of 24
Utility
N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES Useful As CCR6 Inhibitors
25 Mar 20
Brian Stephen Gerstenberger, Andrew Christopher Flick, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, JR., Mark Edward Schnute, Daniel Wei-Shung Kung, Daniel Copley Schmitt, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
Filed: 19 Sep 19
Utility
Non-lipidated Variants of Neisseria Meningitidis ORF2086 Antigens
25 Mar 20
The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof.
Annaliesa Sybil Anderson, Kathrin Ute Jansen, Mark Edward Ruppen, Justin Keith Moran, Susan Kay Hoiseth
Filed: 9 Oct 19
Utility
Compositions Relating to a Mutant Clostridium Difficile Toxin and Methods Thereof
25 Mar 20
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G.K. Donald, Maninder K. Sidhu, Narender Kumar Kalyan, Justin Keith Moran, Mark Edward Ruppen, Michael James Flint
Filed: 4 Dec 19
Utility
ANTIBODIES TO COAGULATION FACTOR XIa AND USES THEREOF
25 Mar 20
In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided.
Thomas MIKITA, Lauren K. ELY, Huilan GAO, Yun KIM, Isaac J. RONDON, Tovo DAVID, Shaun R. COUGHLIN
Filed: 21 Jul 16
Utility
ANTI-AVB8 Antibodies and Compositions and Uses Thereof
11 Mar 20
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to αvβ8 integrin.
Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akhurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
Filed: 4 Sep 19
Utility
Antibodies and Antibody Fragments for Site-specific Conjugation
4 Mar 20
The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.
Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
Filed: 18 Nov 19
Utility
Compounds and Methods of Use
4 Mar 20
This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity.
Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Naveen Chaklan, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
Filed: 21 Oct 19
Utility
Combinations For Treatment Of NASH/NAFLD And Related Diseases
4 Mar 20
The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
William Paul Esler, Trenton Thomas Ross
Filed: 27 Aug 19
Utility
Escherichia Coli Compositions and Methods Thereof
26 Feb 20
In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof.
Robert G.K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
Filed: 6 Aug 19
Utility
Tyrosine Prototrophy
19 Feb 20
Provided herein is a tyrosine selection marker system, and uses thereof.
Gregory Walter HILLER, Jeffrey Joseph MITCHELL, Bhanu Chandra MULUKUTLA, Pamela Mary PEGMAN
Filed: 8 Mar 18
Utility
ANTI-GDF15 Antibodies, Compositions and Methods of Use
19 Feb 20
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
Kevin Charles Beaumont, Danna M. Breen, Matthew Allister Lambert, Jeffrey Raymond Chabot, Tao He, Ksenya Shchors, James R. Apgar
Filed: 14 Aug 19
Utility
SGLT-2 Inhibitors for Treating Metabolic Disorders In Patients with Renal Impairment or Chronic Kidney Disease
19 Feb 20
The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
Ramachandra G. Naik, Elizabeth S. Ommen, James Michael Rusnak, Steven G. Terra
Filed: 24 Oct 19
Utility
Therapeutic Polymeric Nanoparticles Comprising Lipids and Methods of Making and Using Same
19 Feb 20
The present disclosure generally relates to therapeutic nanoparticles.
Young-Ho Song
Filed: 16 Oct 17
Utility
Combination of an ANTI-PD-L1 Antibody and a Dna-pk Inhibitor for the Treatment of Cancer
12 Feb 20
The present invention relates to combination therapies useful for the treatment of cancer.
Astrid Zimmermann, Lars Damstrup, Anne-Kathrin Prokein, Andreas Schroeder
Filed: 26 Mar 18
Utility
Methods of Treating or Reducing the Risk of Cardiovascular Events and Relted Diseases Using SGLT-2 Inhibitors
5 Feb 20
The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
Brett Lauring, Samuel S. Engel, Steven G. Terra, James M. Rusnak
Filed: 9 Oct 19
Utility
Compositions and Methods for Treatment of Abnormal Cell Growth
5 Feb 20
This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
Mahesh Padval, Paul Okwabi Nkansah
Filed: 10 Mar 19
Utility
Aminopyrimidinyl Compounds
5 Feb 20
Andrew FENSOME, Ariamala GOPALSAMY, Brian S. GERSTENBERGER, Ivan Viktorovich EFREMOV, Zhao-Kui WAN, Betsy PIERCE, Jean-Baptiste TELLIEZ, John I. TRUJILLO, Liying ZHANG, Li XING, Eddine SAIAH
Filed: 23 Sep 19
Utility
RORC2 Inhibitors and Methods of Use Thereof
5 Feb 20
The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, Jr., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
Filed: 17 Oct 19
Utility
Cyclic Substituted IMIDAZO[4,5-C]QUINOLINE Derivatives
5 Feb 20
Thomas Allen Chappie, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Antonia Friederike Stepan, Travis T. Wager
Filed: 28 Feb 18
Utility
Composition Comprising Avelumab
29 Jan 20
The present invention relates to avelumab antibody compositions with an elevated deamidation level, as well as methods for using such compositions to treat a disorder, e.g., a disorder in which the interaction between PD-1 and PD-L1 is detrimental.
MARIA GRAZIA TERLIZZESE, FRANCESCA CAVALIERE, ANNA R. PEZZOTTI, ELIO DE ROSSI
Filed: 4 Mar 18